Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma

Overview

Journal Front Genet

Date 2019 Oct 18

PMID 31620167

Citations 15

Authors

Claire Gourzones

Caroline Bret

Jerome Moreaux

Affiliations

Soon will be listed here.

Abstract

Multiple myeloma (MM) is a malignancy characterized by accumulation of malignant plasma cells within the bone marrow (BM). MM is considered mostly without definitive treatment because of the inability of standard of care therapies to overcome drug-resistant relapse. Genotoxic agents are used in the treatment of MM and exploit the fact that DNA double-strand breaks are highly cytotoxic for cancer cells. However, their mutagenic effects are well-established and described. According to these effects, chemotherapy could cause harmful DNA damage associated with new driver genomic abnormalities providing selective advantage, drug resistance, and higher relapse risk. Several mechanisms associated with MM cell (MMC) resistance to genotoxic agents have been described, underlining MM heterogeneity. The understanding of these mechanisms provides several therapeutic strategies to overcome drug resistance and limit mutagenic effects of treatment in MM. According to this heterogeneity, adopting precision medicine into clinical practice, with the development of biomarkers, has the potential to improve MM disease management and treatment.

Citing Articles

The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review.

Almodovar Diaz A, Alouch S, Chawla Y, Gonsalves W Blood Lymphat Cancer. 2024; 14:71-87.

PMID: 39664714 PMC: 11631777. DOI: 10.2147/BLCTT.S490021.

Progression of monoclonal gammopathy of undetermined significance to multiple myeloma is associated with enhanced translational quality control and overall loss of surface antigens.

Ravn Berg S, Dikic A, Sharma A, Hagen L, Vagbo C, Zatula A J Transl Med. 2024; 22(1):548.

PMID: 38849800 PMC: 11162064. DOI: 10.1186/s12967-024-05345-x.

Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma.

Bruyer A, Dutrieux L, de Boussac H, Martin T, Chemlal D, Robert N Front Oncol. 2023; 13:1271847.

PMID: 38125947 PMC: 10730928. DOI: 10.3389/fonc.2023.1271847.

The Impact of Metformin on the Development of Hypothyroidism and Cardiotoxicity Induced by Cyclophosphamide, Methotrexate, and Fluorouracil in Rats.

Alhowail A, Aldubayan M Pharmaceuticals (Basel). 2023; 16(9).

PMID: 37765120 PMC: 10535803. DOI: 10.3390/ph16091312.

Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy.

Xing L, Liu Y, Liu J Cancers (Basel). 2023; 15(8).

PMID: 37190168 PMC: 10137208. DOI: 10.3390/cancers15082240.

References

Arai A, Chano T, Futami K, Furuichi Y, Ikebuchi K, Inui T . RECQL1 and WRN proteins are potential therapeutic targets in head and neck squamous cell carcinoma. Cancer Res. 2011; 71(13):4598-607. DOI: 10.1158/0008-5472.CAN-11-0320. View

Futami K, Kumagai E, Makino H, Sato A, Takagi M, Shimamoto A . Anticancer activity of RecQL1 helicase siRNA in mouse xenograft models. Cancer Sci. 2008; 99(6):1227-36. PMC: 11159650. DOI: 10.1111/j.1349-7006.2008.00794.x. View

Landau H, McNeely S, Nair J, Comenzo R, Asai T, Friedman H . The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Mol Cancer Ther. 2012; 11(8):1781-8. DOI: 10.1158/1535-7163.MCT-11-0949. View

Kirschner K, Melton D . Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs. Anticancer Res. 2010; 30(9):3223-32. View

Roddam P, Rollinson S, ODriscoll M, Jeggo P, Jack A, Morgan G . Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. J Med Genet. 2002; 39(12):900-5. PMC: 1757220. DOI: 10.1136/jmg.39.12.900. View

Grogan T, Spier C, Salmon S, Matzner M, Rybski J, Weinstein R . P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood. 1993; 81(2):490-5. View

Ruffner H, Jiang W, Craig A, Hunter T, Verma I . BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site. Mol Cell Biol. 1999; 19(7):4843-54. PMC: 84283. DOI: 10.1128/MCB.19.7.4843. View

Braggio E, Kortum K, Stewart A . SnapShot: Multiple Myeloma. Cancer Cell. 2015; 28(5):678-678.e1. PMC: 4864595. DOI: 10.1016/j.ccell.2015.10.014. View

Shah M, Martinez-Garcia E, Phillip J, Chambliss A, Popovic R, Ezponda T . MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents. Oncogene. 2016; 35(45):5905-5915. PMC: 6071667. DOI: 10.1038/onc.2016.116. View

10.

Alagpulinsa D, Ayyadevara S, Yaccoby S, Shmookler Reis R . A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition. Mol Cancer Ther. 2016; 15(2):241-50. PMC: 4747838. DOI: 10.1158/1535-7163.MCT-15-0660. View

11.

Hassen W, Kassambara A, Reme T, Sahota S, Seckinger A, Vincent L . Drug metabolism and clearance system in tumor cells of patients with multiple myeloma. Oncotarget. 2015; 6(8):6431-47. PMC: 4467447. DOI: 10.18632/oncotarget.3237. View

12.

Simsek D, Furda A, Gao Y, Artus J, Brunet E, Hadjantonakis A . Crucial role for DNA ligase III in mitochondria but not in Xrcc1-dependent repair. Nature. 2011; 471(7337):245-8. PMC: 3261757. DOI: 10.1038/nature09794. View

13.

Podar K, Chauhan D, Anderson K . Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2008; 23(1):10-24. PMC: 3418600. DOI: 10.1038/leu.2008.259. View

14.

Friedberg E . How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2002; 1(1):22-33. DOI: 10.1038/35094000. View

15.

Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C . Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011; 118(22):5752-8. DOI: 10.1182/blood-2011-05-355081. View

16.

Caraux A, Vincent L, Bouhya S, Quittet P, Moreaux J, Requirand G . Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?. Oncotarget. 2012; 3(11):1335-47. PMC: 4539173. DOI: 10.18632/oncotarget.650. View

17.

Cives M, Ciavarella S, Rizzo F, De Matteo M, Dammacco F, Silvestris F . Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013; 25(5):1108-17. DOI: 10.1016/j.cellsig.2013.01.020. View

18.

Karran P, Bignami M . DNA damage tolerance, mismatch repair and genome instability. Bioessays. 1994; 16(11):833-9. DOI: 10.1002/bies.950161110. View

19.

Herrero A, San Miguel J, Gutierrez N . Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability. PLoS One. 2015; 10(3):e0121581. PMC: 4366222. DOI: 10.1371/journal.pone.0121581. View

20.

Fordham S, Matheson E, Scott K, Irving J, Allan J . DNA mismatch repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs. Leukemia. 2011; 25(6):1046-9. DOI: 10.1038/leu.2011.38. View